logo-loader
viewVerona Pharma

Verona Pharma to use industry conference to expand on lung disease treatment data

Chief medical officer Kathleen Rickard will present the new information on nebulised ensifentrine at the CHEST Annual Meeting in New Orleans

Verona Pharma -
Verona’s second-stage study revealed the treatment to provide “clinically meaningful improvements” in both lung function and symptoms

A senior member of Verona Pharma PLC’s (LON:VRP, NASDAQ:VRNA) scientific team will expand on symptom data from a phase IIb clinical trial of its inhaled drug for chronic obstructive pulmonary disease (COPD).

Chief medical officer Kathleen Rickard will present the new information on nebulised ensifentrine at the CHEST Annual Meeting, being held in New Orleans, next Monday, October 21.

Verona’s second-stage study revealed the treatment to provide “clinically meaningful improvements” in both lung function and symptoms, including breathlessness, in people with moderate-to-severe COPD. It has been well-tolerated in clinical trials involving more than 800 people to date.

COPD is a respiratory disease, which is progressive and life-threatening and is caused by long-term exposure to lung irritants such as tobacco smoke.

The cost of treatment in the US alone is put at US$49bn annually.

Quick facts: Verona Pharma

Price: 57 GBX

AIM:VRP
Market: AIM
Market Cap: £60.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Verona Pharma has compound with 'massive potential to impact lives of COPD...

Verona Pharma PLC (LON:VRP) chairman David Ebsworth tells Proactive London's Andrew Scott the company's made 'massive progress' in the last few years. ''When we started it was really three or four people, we didn't have a  lot of money, we had early data and over the last five years...

on 2/12/19

2 min read